Total
0
Shares
ResApp Health (ASX:RAP) - CEO & Managing Director, Tony Keating
CEO & Managing Director, Tony Keating
Source: TechInvest Magazine
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Digital health company ResApp Health (RAP) has signed a software licensing agreement with Phenix Health
  • This agreement will allow Phenix to use ResApp’s respiratory diagnostic test, ResAppDx-EU, in its telehealth smartphone app from July 1
  • ResAppDx-EU uses machine learning algorithms to analyse a patient’s cough sounds to diagnose diseases and provide quick and accurate information
  • The initial agreement is for a two-year period but it may be extended by mutual agreement or terminated with at least 60-days written notice
  • ResApp is up a steady 11.4 per cent in mid-morning trade and shares are selling for 19.5 cents each

Digital health company ResApp Health (RAP) has signed a software licensing agreement with Phenix Health.

This agreement will allow Phenix to use ResApp’s respiratory diagnostic test, ResAppDx-EU, in its telehealth smartphone app from July 1, 2020.

The initial agreement is for a two-year period but it may be extended by mutual agreement or terminated with at least 60-days written notice.

ResApp will receive a licence fee of $5 to $10 for every test.

“At Phenix, we are establishing a first-of-its-kind virtual respiratory clinic to address the increasing demand we are seeing for more remote acute respiratory disease care. We are excited to be launching ResAppDx-EU on our platform on July 1,” Phenix CEO and Founder Dr Gillian Alexis said.

“Tools such as ResAppDx-EU will allow our doctors to provide the highest levels of care to our patients in the virtual setting,” she added.

ResAppDx-EU is ResApp’s mobile software app which is used by clinicians for the diagnosis for multiple respiratory problems.

It uses machine learning algorithms to analyse a patient’s cough sounds to diagnose the disease and provide quick and accurate information.

It is a software-only solution that can run on smartphones, meaning it does not require any additional hardware or accessories.

ResAppDx-EU has been approved by the Therapeutics Goods Administration (TGA) in Australia and has received CE Mark approval in Europe.

“We are pleased to have partnered with Phenix to integrate ResAppDx-EU into their virtual super clinic,” ResApp CEO and Managing Director Tony Keating commented.

“Our initial launch, via Phenix’s telehealth iOS application, will see our clinically-validated and regulatory-approved diagnostic test available to Phenix’s customers Australia-wide, empowering their doctors to better assess patients presenting with respiratory symptoms such as sore throat, runny nose, shortness-of-breath or cough,” he added.

ResApp is up a steady 11.4 per cent in mid-morning trade and shares are selling for 19.5 cents each at 10:29 am AEST.

RAP by the numbers
More From The Market Herald
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp (ASX:RAP) secures new licences in Q3 amid revenue slump

ResApp Health (RAP) has released its quarterly activities report for the three months to the end of September 2021.

" Incannex Healthcare (ASX:IHL) lands ethics approval for psychedelic-based anxiety treatment trial

Incannex Healthcare (IHL) has spiked on the ASX today after landing important regulatory approvals to trial a psychedelic-based treatment for severe anxiety.